Pallas Health review

The continuing charges are every four weeks

Pallas Health lists compounded semaglutide at $199 every four weeks after a $139 first month, and tirzepatide at $299 every four weeks after a $179 first month. Keep the introduction and renewal period separate. A four-week recurring schedule contains thirteen cycles over 52 weeks, rather than twelve ordinary calendar-month charges.

The company says the compounded price does not rise with dose and includes provider care and shipping. Confirm the actual prescribed quantity and next charge date before relying on that description. A dose-flat promise can make budgeting simpler, but the supply, follow-up and renewal agreement still need to match the particular prescription.

Annual equivalents require a different commitment

Pallas also advertises lower annual-plan averages around $139 for semaglutide and $239 for tirzepatide. Those are prepaid alternatives, not the recurring four-week amounts available without the longer commitment. Ask for the full upfront total, dispensing schedule and conditions before choosing the smaller equivalent.

The financial term matters if the clinician changes treatment or the patient needs to stop. Establish what happens to remaining medication, shipments and payments. A lower average does not create a general refund right for unused time, and a long purchase should not be interpreted as a clinical instruction to continue unchanged throughout the paid period.

The brand route has a separate cost structure

Pallas also lists approved brand products including Wegovy, Ozempic, Zepbound and Mounjaro, with cash-pay options advertised from $1,069 monthly. That starting brand figure should not be assigned to every named product or dose. Obtain a current quote for the exact brand and care arrangement rather than borrowing the compounded injection price.

The program is cash-pay and says it does not bill insurance. Someone comparing it with an insurance-based practice should therefore use the actual payment available under each route, including any separate care charge elsewhere. The presence of an approved brand on a menu does not establish eligibility for a manufacturer offer or a specific insurance benefit.

Named clinicians improve identification, not every eligibility answer

Pallas publicly names Ana Lisa Carr, MD, and Kelly Tenbrink. Earlier verification matched their federal NPI records rather than relying only on the marketing names. That supports professional identification, but an NPI record is not a complete current state-licensure or specialty assessment for an individual patient’s care.

The service claims access in all fifty states and Washington, D.C., with asynchronous entry in forty-three and live video required in seven. Ask which format applies to the intended location and who reviews the assessment. A named professional and a broad coverage claim do not guarantee prescribing approval or establish that the same clinician provides every subsequent contact.

The pharmacy and final-sale terms deserve attention

Pallas does not publicly name the compounding pharmacy in its public information. Obtain the actual dispensing partner, formulation, concentration, quantity, storage and use instructions. Compounded finished products remain distinct from approved brands, and a certification seal does not establish their approval status or replace product-specific information.

Its current terms describe charges as final once a prescription is issued, with cancellation stopping future charges. Clarify the practical deadline before another order and the process for treatment changes. Pallas may interest someone seeking dose-flat compounded care or a separately priced brand route, but the choice depends on the real four-week budget, responsible pharmacy and accessible clinician. The public material does not establish a dedicated postpartum, breastfeeding or PCOS pathway, so those needs require an individual discussion.